SCHEMBL4167003

SCHEMBL4167003

CCN(CC)CCN(C)c1ccc(-c2nc3c(C(=O)NC4CCCCC4)ccnc3[nH]2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
PBK Q96KB5 3/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
TSHR P16473 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ACVR1 Q04771 1/20 0.37
CD38 P28907 3/20 0.37
HSD11B1 P28845 2/20 0.37
GSK3B P49841 1/20 0.36
RAB9A P51151 1/20 0.36
CHEK1 O14757 1/20 0.35
MAP4K4 O95819 1/20 0.35
LCK P06239 1/20 0.35
CSF1R P07333 1/20 0.35
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4144891 0.81 RAD52 (0.42) KDM4EPBKALDH1A1GAAACVR1
SCHEMBL4167014 0.81 GSK3B (0.43) KDM4EALDH1A1HPGDSMN1; SMN2GSK3B
SCHEMBL4152141 0.79 NPC1 (0.48) PBKRAB9A
SCHEMBL4152581 0.79 NPC1 (0.48) PBKRAB9A
SCHEMBL4152149 0.79 PBK (0.54) KDM4EPBKKMT2AMEN1ALDH1A1
SCHEMBL4148191 0.79 GSK3B (0.61) GSK3BCHEK1MAP4K4LCKCSF1R
SCHEMBL4160333 0.78 PBK (0.47) PBKALDH1A1HPGDSMN1; SMN2GSK3B
SCHEMBL4146026 0.77 BMPR1B (0.45) PBKKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL4164571 0.77 PBK (0.47) KDM4EPBKALDH1A1GAACD38
SCHEMBL4153562 0.77 PBK (0.47) KDM4EPBKALDH1A1GAACD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 KDM4E 1174/4885PBK 999/4885KMT2A 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.